Bevacizumab Effective for Macular Edema Due to Central Retinal Vein Occlusion

Source: Medscape

Tuesday, May 16, 2017 | Medical Studies


Bevacizumab is as effective as aflibercept for improving visual acuity in patients with macular edema due to central retinal vein occlusion, according to results from the SCORE2 trial. “Although aflibercept has been demonstrated previously to be associated with superior visual acuity outcomes compared to bevacizumab in patients whose vision is at least moderately impaired due to diabetic macular edema, the SCORE2 Investigative Group found that, among patients with vision impairment due to macular edema associated with central retinal or hemiretinal vein occlusion, bevacizumab was non-inferior to aflibercept at 6 months with respect to visual acuity after 6 months of treatment, based on a non-inferiority margin of 5 letters of vision,” said Dr. Ingrid U. Scott from Penn State College of Medicine in Hershey, Pennsylvania.

Open in New Window

Comments

You must be logged in to leave a comment.